Name of journal: World Journal of Clinical Cases

Manuscript NO: 66006

Title: Encouraging Specific Biomarkers-based Therapeutic Strategies for Hepatocellular Carcinoma

Reviewer’s code: 05947170

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer’s Country/Territory: China

Author’s Country/Territory: China

Manuscript submission date: 2021-03-19

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2021-03-29 11:53

Reviewer performed review: 2021-04-06 04:35

Review time: 7 Days and 16 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>Grade B: Very good</th>
<th>Grade C: Good</th>
<th>Grade D: Fair</th>
<th>Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>Grade A: Priority publishing</td>
<td>Grade B: Minor language polishing</td>
<td>Grade C: A great deal of language polishing</td>
<td>Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>Accept (High priority)</td>
<td>Accept (General priority)</td>
<td>Minor revision</td>
<td>Major revision</td>
<td>Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>Yes</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peer-review statements</td>
<td>Peer-Review: Anonymous</td>
<td>Onymous</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conflicts-of-Interest</td>
<td>Yes</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS
This article reviews the biomarkers related to immunotherapy of hepatocellular carcinoma, which has very important practical significance for the combination therapy strategy of hepatocellular carcinoma. However, there were several limitations in the manuscript: 1) The biomarkers listed in the manuscript are not complete, have the corresponding therapeutic drugs for the relevant biomarkers been developed, and what is the effect? 2) Whether there are any correlations between the biomarkers, what is the correlation between them and immunotherapy, respectively. Lack of some experimental data support in vitro and in vivo. It is recommended that each biomarker and pathway be listed separately.